Emergent BioSolutions (NYSE:EBS) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $(0.25) by 184 percent. This is a 71.62 percent decrease over earnings of $0.74 per share from the same period last year. The company reported quarterly sales of $156.100 million which beat the analyst consensus estimate of $145.000 million by 7.66 percent. This is a 29.75 percent decrease over sales of $222.200 million the same period last year.